Inflammatory biomarkers for non-metastatic kidney cancer

This study looked at inflammatory biomarkers in the blood for the diagnosis of non-metastatic renal cell carcinoma (RCC).  Inflammation is known to be associated with cancer, and there have been a number of studies that have looked at the relationship between cancer and inflammatory biomarkers. Inflammatory biomarkers such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte […]

read more

Inflammatory biomarkers to predict outcomes in kidney cancer

There still remains the need for a reliable biomarker to predict outcomes for advanced kidney cancer patients. Scientists have been working hard to try to identify biomarkers that can predict clinical outcomes and the course of the disease in people with metastatic renal cell carcinoma (RCC). A recent study published in Pathology Oncology Research this […]

read more

Potential biomarker to predict outcomes in metastatic kidney cancer

A recent study published in Targeted Oncology last month investigates the role of an enzyme called γ-glutamyltransferase (GGT) as a potential biomarker for metastatic renal cell carcinoma (RCC). High levels of GGT in the blood has been linked with poor survival in various cancers; however, there are no data for metastatic RCC patients. This study […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

A potential biomarker for survival for non-metastatic kidney cancer

A recent study published in the journal International Urology and Nephrology this month evaluates mean platelet volume-to-lymphocyte ratio (MPVLR) as a biomarker for survival in patients undergoing nephrectomy for non-metastatic clear cell renal cell carcinoma (ccRCC). In the study, 344 patients with proven ccRCC that has not spread (non-metastatic) were treated with radical or partial […]

read more

Predictive biomarkers for kidney cancer

At the Society of Urologic Oncology (SUO) conference in Washington, USA last week, Dr Joshua Lang discussed the future of predictive biomarkers in renal cell carcinoma (RCC). The treatment of kidney cancer is evolving with first-line combination therapies, including nivolumab plus ipilimumab and axitinib plus pembrolizumab, and first-line drug options that depend on risk of […]

read more

IKCS 2019: Biomarkers in kidney cancer

In this interview taken from the International Kidney Cancer Symposium (IKCS) 2019 held in Miami, USA earlier this month, Dr Tian Zhang, from Duke University talks about existing and emerging immunotherapy biomarkers for kidney cancer, and the PEDIGREE study. Dr Zhang talks about PBRM1, PD-L1, and tumour mutational burden as prognostic biomarkers, and angiogenesis, CD8-infiltrating […]

read more

PD-L1 can be used to predict the likely course of kidney cancer

A recently published study evaluated the role of programmed-death receptor ligand (PD-L1) as an indicator of the likely course (prognosis) of clear cell renal cell carcinoma (RCC). A total of 738 patients were included in the study and followed for around 34 months. The presence of PD-L1 and PD-1 receptors in the tumour cells was […]

read more

MicroRNA as a marker for kidney cancer

A recent study has provided evidence that a group of microRNAs, called the miRNA-200 family, can be used to predict the likely course of clear cell renal cell carcinoma (RCC). MicroRNAs (miRNAs) are small pieces of RNA (nucleic acid that is found in all living cells) that act as messengers to regulate the synthesis of […]

read more

Potential prognostic marker for kidney cancer

A recent study to be published in Clinical and Experimental Medicine next month investigates the role of microRNAs (miRNAs) in the development of renal cell carcinoma (RCC) and the levels of miRNA-15a in RCC tumours. The investigators showed that increased miRNA-15a was associated with indicators of poor prognosis, such as high Fuhrman grade, the presence […]

read more
Showing 1 to 10 of 20 results
  TOP